These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34667106)

  • 1. Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns.
    Dong Y; Sui Y; Cheng X; Wang DZ
    Stroke Vasc Neurol; 2022 Feb; 7(1):1-5. PubMed ID: 34667106
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States.
    Qureshi AI; Baskett WI; Bains NK; French BR; Siddiq F; Gomez CR; Shyu CR
    J Stroke Cerebrovasc Dis; 2023 Feb; 32(2):106898. PubMed ID: 36493706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety of tenecteplase vs alteplase for acute ischemic stroke.
    Flint AC; Eaton A; Melles RB; Hartman J; Cullen SP; Chan SL; Rao VA; Nguyen-Huynh MN; Kapadia B; Patel NU; Klingman JG
    J Stroke Cerebrovasc Dis; 2024 Jan; 33(1):107468. PubMed ID: 38039801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
    Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study.
    Li S; Pan Y; Wang Z; Liang Z; Chen H; Wang D; Sui Y; Zhao X; Wang Y; Du W; Zheng H; Wang Y
    Stroke Vasc Neurol; 2022 Feb; 7(1):47-53. PubMed ID: 34429364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major Bleeding Postadministration of Tenecteplase Versus Alteplase in Acute Ischemic Stroke.
    Walton MN; Hamilton LA; Salyer S; Wiseman BF; Forster AM; Rowe AS
    Ann Pharmacother; 2023 May; 57(5):535-543. PubMed ID: 36004394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Thrombolytics: from Alteplase to Tenecteplase.
    Miller SE; Warach SJ
    Neurotherapeutics; 2023 Apr; 20(3):664-678. PubMed ID: 37273127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and predictors of stroke mimics in young patients in the norwegian tenecteplase stroke trial (NOR-TEST).
    Jacobsen E; Logallo N; Kvistad CE; Thomassen L; Idicula T
    BMC Neurol; 2023 Nov; 23(1):406. PubMed ID: 37968581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations.
    Hailu K; Cannon C; Hayes S
    Am J Health Syst Pharm; 2022 Jun; 79(12):944-949. PubMed ID: 35020806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
    Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
    Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making a case for the right '-ase' in acute ischemic stroke: alteplase, tenecteplase, and reteplase.
    Chester KW; Corrigan M; Schoeffler JM; Shah M; Toy F; Purdon B; Dillon GM
    Expert Opin Drug Saf; 2019 Feb; 18(2):87-96. PubMed ID: 30712409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
    Huang X; Moreton FC; Kalladka D; Cheripelli BK; MacIsaac R; Tait RC; Muir KW
    Stroke; 2015 Dec; 46(12):3543-6. PubMed ID: 26514192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.
    Campbell BCV; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Dowling RJ; Yan B; Bush SJ; Dewey HM; Thijs V; Scroop R; Simpson M; Brooks M; Asadi H; Wu TY; Shah DG; Wijeratne T; Ang T; Miteff F; Levi CR; Rodrigues E; Zhao H; Salvaris P; Garcia-Esperon C; Bailey P; Rice H; de Villiers L; Brown H; Redmond K; Leggett D; Fink JN; Collecutt W; Wong AA; Muller C; Coulthard A; Mitchell K; Clouston J; Mahady K; Field D; Ma H; Phan TG; Chong W; Chandra RV; Slater LA; Krause M; Harrington TJ; Faulder KC; Steinfort BS; Bladin CF; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM;
    N Engl J Med; 2018 Apr; 378(17):1573-1582. PubMed ID: 29694815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenecteplase use in patients with acute ischaemic stroke.
    Menon BK; Singh N; Sylaja PN
    Lancet; 2023 Feb; 401(10377):618-619. PubMed ID: 36774934
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit-TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit.
    Bivard A; Zhao H; Coote S; Campbell B; Churilov L; Yassi N; Yan B; Valente M; Sharobeam A; Balabanski A; Dos Santos A; Ng F; Langenberg F; Stephenson M; Smith K; Bernard S; Thijs V; Cloud G; Choi P; Ma H; Wijeratne T; Chen C; Olenko L; Davis SM; Donnan GA; Parsons M
    BMJ Open; 2022 Apr; 12(4):e056573. PubMed ID: 35487712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
    Zhong CS; Beharry J; Salazar D; Smith K; Withington S; Campbell BCV; Wilson D; Le Heron C; Mason D; Duncan R; Reimers J; Mein-Smith F; Diprose WK; Barber PA; Ranta A; Fink JN; Wu TY
    Stroke; 2021 Mar; 52(3):1087-1090. PubMed ID: 33588597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and predictors of stroke mimics in The Norwegian Tenecteplase Stroke Trial (NOR-TEST).
    Kvistad CE; Novotny V; Næss H; Hagberg G; Ihle-Hansen H; Waje-Andreassen U; Thomassen L; Logallo N
    Int J Stroke; 2019 Jul; 14(5):508-516. PubMed ID: 30019629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale.
    Rønning OM; Logallo N; Thommessen B; Tobro H; Novotny V; Kvistad CE; Aamodt AH; Næss H; Waje-Andreassen U; Thomassen L
    Stroke; 2019 Feb; 50(2):498-500. PubMed ID: 30602354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review and meta-analysis.
    Ma P; Zhang Y; Chang L; Li X; Diao Y; Chang H; Hui L
    J Neurol; 2022 Oct; 269(10):5262-5271. PubMed ID: 35776193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical analysis plan for the randomized controlled trial Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST).
    Eltoft A; Wilsgaard T; Roaldsen MB; Søyland MH; Lundström E; Petersson J; Indredavik B; Putaala J; Christensen H; Kõrv J; Jatužis D; Engelter ST; De Marchis GM; Werring DJ; Robinson T; Tveiten A; Mathiesen EB
    Trials; 2022 May; 23(1):421. PubMed ID: 35590386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.